Gene diagnosis composition and kit for predicting clopidogrel resistance of patient with stable angina
A technology for clopidogrel resistance and genetic diagnosis, applied in the biological field, can solve problems such as increased risk of bleeding, adverse cardiovascular events, and endangering the lives of patients
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0059] Example 1: circRNAs composition and method for predicting clopidogrel resistance in patients with stable angina
[0060] 1. Experimental sample
[0061] Selected patients with coronary heart disease planned for PCI from Hunan Provincial People's Hospital from January 2016 to December 2017, and divided the patients with coronary heart disease into stable angina pectoris group according to the preoperative diagnosis (coronary angiography and electrocardiogram, etc.) ( SAP group), unstable angina group (UA group), ST-segment elevation myocardial infarction group (STEMI group) and non-ST-segment elevation myocardial infarction group (NSTEMI group). Before the operation, they were pre-treated with clopidogrel tablets (Polivix) with a loading dose of 300 mg. The maximum platelet aggregation rate (MPAR) induced by 5μM adenosine diphosphate was detected before and 12 hours after the drug. At the same time, the plasma before the drug was measured. The relative expression level of ta...
Embodiment 2
[0092] Example 2: circRNAs composition and method for predicting clopidogrel resistance in patients with unstable angina pectoris
[0093] 1. Experimental sample
[0094] The same as in Example 1.
[0095] 2. Experimental method
[0096] 1. Total RNA extraction and quality inspection
[0097] Follow the instructions of the TaKaRa RNAiso Blood kit. Take 250μL of plasma from each sample to extract the total RNA in the plasma sample. Use a spectrophotometer to determine the optical density D(260) and D(280) values of total RNA, use D(260) value to calculate its concentration, and calculate D(260) / D(280) value to detect its purity, D(260) ) / D(280) value range of 1.8~2.1 is considered qualified.
[0098] 2. Real-time fluorescence quantitative PCR to detect target circRNAs
[0099] Operate according to the instructions of PrimeScript RT reagent Kit with gDNAEraser kit. The real-time fluorescent quantitative PCR primers for the target circRNAs and internal reference GAPDH were designed and ...
Embodiment 3
[0121] Example 3: circRNAs composition and method for predicting clopidogrel resistance in patients with ST-segment elevation myocardial infarction
[0122] 1. Experimental sample
[0123] The same as in Example 1.
[0124] 2. Experimental method
[0125] 1. Total RNA extraction and quality inspection
[0126] Follow the instructions of the TaKaRa RNAiso Blood kit. Take 250μL of plasma from each sample to extract the total RNA in the plasma sample. Use a spectrophotometer to determine the optical density D(260) and D(280) values of total RNA, use D(260) value to calculate its concentration, and calculate D(260) / D(280) value to detect its purity, D(260) ) / D(280) value range of 1.8~2.1 is considered qualified.
[0127] 2. Real-time fluorescence quantitative PCR to detect target circRNAs
[0128] Operate according to the instructions of PrimeScript RT reagent Kit with gDNAEraser kit. The real-time fluorescent quantitative PCR primers for the target circRNAs and internal reference GAPDH ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


